Jon Lim is a Managing Partner who joined F-Prime in 2011 to launch our dedicated efforts in Healthtech + Services. His investments include F-Prime’s investments in Liazon (acquired by Towers Watson), PatientPing (acquired by Appriss Heath, now Bamboo Health), VitalWare (acquired by Health Catalyst), Artemis Health (acquired by Nomi Health), Lumere (acquired by Global Healthcare Exchange), Blue Rabbit (acquired by Wedgewood Pharmacy), Protenus (acquired by Bluesight), Benchling, BenchSci, Centivo, Equip Health, Kyruus, NOCD, OncoveryCare, Proximie, Rippl, TraceLink, US HealthVest and WelbeHealth. Jon was previously a Principal at Polaris Partners, where he was part of the teams that led investments in Phytel (acquired by IBM), Egnyte, Recurly, and Ocular Therapeutix (NASDAQ: OCUL). Jon began his investing career in 2002 as an Associate at Summit Partners, where his investments include MDVIP (acquired by Procter & Gamble) and Diagnostic Hybrids (acquired by Quidel). Jon also worked previously at Medtronic in their cardiac rhythm and disease management business.
Jon holds an M.B.A. from Harvard Business School and an A.B. in East Asian Studies from Harvard College, where he graduated magna cum laude.
Stephen Knight joined F-Prime in 2003 where he serves as President and Senior Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 30 years and invests broadly across healthcare. Steve serves on the Board of Directors of Atalanta Therapeutics, Leyden Labs, Paradigm, Quantum Circuits, Inc. (QCI), Skyline Therapeutics, and Xaira Therapeutics. Steve previously served on the boards of several private and public health care companies including Beam Therapeutics (NASDAQ: BEAM), Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (1801.HK), Iora Health (acquired by One Medical), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Prime Medicine (NASDAQ: PRME), Respivert, Ltd (acquired by J&J), Sana Biotechnology (NASDAQ: SANA), and Semma Therapeutics (acquired by Vertex).
Prior to joining F-Prime, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an MD from the Yale University School of Medicine, and an MBA from the Yale School of Organization and Management and received a BS in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.